Document is current

Article History

Received: 6 July 2023

Accepted: 13 September 2023

First Online: 29 September 2023

Declarations

:

: All experiments and handling of mice was performed in compliance with the German animal welfare law and with approval from the Government of Upper Bavaria. CSF was sampled under the animal license: ROB 55.2–2532.Vet_02-15-69. All experiments including iPSCs were performed in compliance with all applicable guidelines and regulations. All participants were enrolled in ARTFL (U54NS092089) or LEFFTDS (U01AG045390), together ALLFTD, which is a North American research consortium to study sporadic and familiar FTD. All CSF from the ALLFTD consortium were approved and provided by the National Centralized Repository for Alzheimer’s Disease and Related Dementias (NCRAD).

: Not applicable.

: CH collaborates with Denali Therapeutics. HZ has served at scientific advisory boards and/or as a consultant for Abbvie, Acumen, Alector, Alzinova, ALZPath, Annexon, Apellis, Artery Therapeutics, AZTherapies, CogRx, Denali, Eisai, Nervgen, Novo Nordisk, Optoceutics, Passage Bio, Pinteon Therapeutics, Prothena, Red Abbey Labs, reMYND, Roche, Samumed, Siemens Healthineers, Triplet Therapeutics, and Wave, has given lectures in symposia sponsored by Cellectricon, Fujirebio, Alzecure, Biogen, and Roche, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program (outside submitted work).